716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer - Jean-Yves Blay; Antoine Italiano; Stephane Champiat; Paolo Antonio Ascierto; Manish Sharma; Jeeyun Lee; Luis Paz-Ares Rodriguez; Keun-Wook Lee; Yoon-Koo Kang; Drew Rasco; Edith A Perez; Mariano Ponz-Sarvise; et al. (Journal for ImmunoTherapy of Cancer, 2023)